07:00 , Jun 4, 2007 |  BC Week In Review  |  Company News

AnalytiCon, Merck KGaA deal

AnalytiCon will use its MEGAbolite technology to identify, isolate, purify and characterize natural products from plant and microbial extracts to treat undisclosed diseases for MRK, which will perform high throughput screening. The companies will co-develop...
07:00 , Jul 4, 2005 |  BC Week In Review  |  Company News

AnalytiCon, Evolva Biotech SA deal

The companies partnered to produce and optimize nuclear hormone receptor agonists. The deal combines Evolva's Watchmaker yeast-based technology with AnalytiCon's MEGAbolite technology. Watchmaker builds combinatorial genetic libraries in yeast, manages growth of the yeast so...
07:00 , Apr 18, 2005 |  BC Week In Review  |  Company News

AnalytiCon, Bionaut deal

The companies partnered to identify and optimize compounds that inhibit the ability of tumor cells to survive under stress conditions. Bionaut will provide compounds, and AnalytiCon will use its natural product and medicinal chemistry capabilities...
01:24 , Apr 15, 2005 |  BC Extra  |  Company News

Bionaut, AnalytiCon in cancer deal

Bionaut (Cambridge, Mass.) and AnalytiCon Discovery (Potsdam, Germany) partnered to identify and optimize cancer compounds. Bionaut will provide compounds that have shown in vivo activity in human tumor xenograft models and will validate the compounds...
07:00 , Jul 19, 2004 |  BC Week In Review  |  Company News

AnalytiCon, Kyowa Hakko Kogyo Co. Ltd. deal

The companies extended their 2002 compound library discovery deal. AnalytiCon is developing libraries using its NatDiverse technology, which combines natural and combinatorial chemistry, and Kyowa is responsible for identifying, validating and developing any compounds. AnalytiCon...
08:00 , Feb 12, 2001 |  BC Week In Review  |  Company News

AnalytiCon, Boehringer Ingelheim deal

AnalytiCon will deliver natural product libraries of more than 10,000 compounds to Boehringer in exchange for up to DM8 million ($3.8 million). Boehringer will have exclusive rights to use the libraries for therapeutic development. AnalytiCon...
08:00 , Oct 30, 2000 |  BC Week In Review  |  Company News

AnalytiCon, Schering-Plough deal

AnalytiCon will use its MEGAbolite process to isolate, purify and characterize natural products generated from microbial extracts for SGP. AnalytiCon Discovery GmbH, Potsdam, Germany   Schering-Plough Corp. (SGP), Kenilworth, N.J.   Business: Drug discovery  ...
07:00 , Oct 23, 2000 |  BC Extra  |  Company News

AnalytiCon analysis deal with Schering-Plough

AnalytiCon Discovery (Pottsdam, Germany) will use its MEGAbolite process to isolate, purify, and characterize natural products generated from microbial extracts for SGP. The company spun off from AnalytiCon AG in June....
07:00 , Oct 4, 1999 |  BC Week In Review  |  Company News

AnalytiCon AG, Bayer deal

Bayer will pay AnalytiCon up to DM6 million ($3.2 million) to use its Sepbox separation and high throughput structure elucidation (HITSE) technology to isolate, purify and characterize natural products from Bayer's biomaterials. AnalytiCon AG ,...
07:00 , Jun 29, 1998 |  BioCentury  |  Emerging Company Profile

Noxxon Pharma AG

Noxxon Pharma AG Berlin, Germany Technology: Mirror image nucleic acids (spiegelmers) Disease focus: Cancer and chronic pain Clinical status: Preclinical Founded: 1997 by Jens Fürste, Thomas Klein, Sven Klußmann, and AnalytiCon AG Corporate partners: Grunenthal...